Efficacy of Tenofovir and Emtricitabine in ARV-naive Patients With HIV/HBV Co-infection
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
Combination therapy with anti-HBV activity may both increase HBV suppression rates and reduce
emergence of resistant strains. Several new therapeutic agents are currently in development,
however combination therapy trials in the HBV-infected population have only recently
commenced. No such trials have been undertaken in the HIV/HBV co-infected population.
Phase:
Phase 2
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration